Skip to main content

Lofexidine News

FDA Approves Lucemyra (lofexidine hydrochloride) as the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms

May 16, 2018 – The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Opiate Withdrawal

Lofexidine patient information at Drugs.com